CORRELATION OF CYTOGENETICS AND GRADE OF BONE MARROW FIBROSIS IN PRIMARY MYELOFIBROSIS
Abstract
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis. Fibrosis often complicates bone marrow aspiration and biopsy, further hindering disease diagnosis. Despite this, cytogenetic analysis is possible from bone marrow aspirate or peripheral blood. Karyotype is an independent prognostic parameter in primary myelofibrosis. The prognostic significance of bone marrow fibrosis grade in primary myelofibrosis remains debatable. This study aimed to investigate the impact of bone marrow fibrosis on overall survival in patients with primary myelofibrosis, as well as to examine the correlation between karyotype and bone marrow fibrosis grade in these patients.
Materials and Methods: The study of the correlation between karyotype and bone marrow fibrosis grade included 120 out of 136 patients with primary myelofibrosis. We used the stratification of chromosomal abnormalities according to the recommendations of prognostic scoring systems: Lille, Mayo, International, and Dynamic International. Karyotype analysis was performed using the conventional cytogenetic method. Bone marrow biopsies of patients were stained using the Gordon-Sweet method.
Results: In 136 patients with primary myelofibrosis, no statistically significant difference in survival was observed (p = 0.084) regardless of the bone marrow fibrosis grade. Additionally, no correlation was found between karyotype or chromosomal aberrations of varying risk levels and bone marrow fibrosis grade (Lille p = 0.293; Mayo p = 0.108; International Prognostic Scoring System p = 0.086; Dynamic International Prognostic Scoring System p = 0.613) in 120 patients with primary myelofibrosis.
Conclusion: Although we did not establish a correlation between karyotype and bone marrow fibrosis grade, we believe that both parameters should be incorporated into new prognostic scoring systems for primary myelofibrosis.
References
Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP, Sabattini E, et al. The classification of myeloproliferative neoplasms: rationale, historical background and future perspectives with focus on unclassifiable cases. Cancers (Basel). 2021 Nov 12;13(22):5666. doi: 10.3390/cancers13225666.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 Sep 15;140(11):1200-1228.doi: 10.1182/blood.2022015850.
Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996 Aug 1;88(3):1013-8. doi: 10.1182/blood.V88.3.1013.1013.
Tefferi A, Gangat N, Animesh Pardanani A, Crispino JD. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 2022 Mar 3;82(5):749–763. doi: 10.1158/0008-5472.CAN-21-2930.
Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, et al. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet. 2007 Feb;173(1):57-62. doi:10.1016/j.cancergencyto.2006.09.021.
Đorđević V, Denčić-Fekete M, Jovanović J, Soldatović I, Janković G, Bogdanović A. Significance of cytogenetic-risk categories and refined international prognostic scoring system for overall survival in primary myelofibrosis: a single-center experience. Vojnosanit Pregl. 2020;77(5):516-24. doi: 10.2298/VSP171129117D.
Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumors of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC Press; 2008. p. 44-7.
Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, Walt JVD, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug 90(8):1128-32. Available from: https://haematologica.org/article/view/3634.
Arber DA, Orazi A, Hasserjian R, Tkiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Erratum in: Blood. 2016 Jul 21;128(3):462-3. doi:10.1182/blood-2016-06-721662.
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002 Oct 1;100(7): 2292-302.doi: 10.1182/blood-2002-04-1199.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262.
Novak A, Kruskic M, Ludoski M, Jurukovski V. Rapid method for obtaining high-quality chromosome banding in the study of hematopoietic neoplasia. Cancer Genet Cytogenet. 1994 Jun;74(2):109-14. doi: 10.1016/0165-4608(94)90007-8.
Hastings RJ, Moore S, Chia N, editors. ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024). Cytogenet Genome Res. 2024;164(Suppl 1):1-224. doi: 10.1159/000538512.
Bauermeister DE. Quantitation of Bone Marrow Reticulin-A Normal Range. Am J Clin Pathol. 1971 Jul;56(1):24-31. doi: 10.1093/ajcp/56.1.24.
Tefferi A, Dingli D, Li CY, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005 Oct 15;104(8):1656-60. doi: 10.1002/cncr.21358.
Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System – independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010 Jan 21;115(3):496-9. doi: 10.1182/blood-2009-08-240135.
Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011 Jan;25(1):82-8. doi: 10.1038/leu.2010.234.
Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol. 2014 Nov;27(11):1447-54. doi: 10.1038/modpathol.2014.69.
Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, et. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023 Jan;482(1):53-68. doi: 10.1007/s00428-022-03480-8.
